| Rebif (human IFN-β-1a) / EMD Serono |
ACTRN12622000094774: INFINiTE-CV2 Phase I Trial: INterFeron type 1 Intra-Nasal gel Therapy for Early treatment of SARS-CoV2 (COVID-19) |
|
|
| Not yet recruiting | 1 | 20 | | | Dr Edmund Lau, IntraVital | COVID-19 | | | | |
| Completed | 1 | 24 | Europe | Interferon beta-1a HSA-free biosimilar, Bioferon®, Interferon beta-1a HSA+ biosimilar, Interferon beta-1a original, Rebif® | Centre Hospitalier Universitaire Vaudois, BioPartners GmbH | Multiple Sclerosis, Relapsing-Remitting | 07/06 | 07/06 | | |
NCT01074593: Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects |
|
|
| Completed | 1 | 20 | RoW | Interferon beta-1a | Azidus Brasil | Healthy | 03/11 | 07/11 | | |
NCT00618527: Combination Therapy Using Cellcept and Rebif in RRMS |
|
|
| Completed | 1 | 31 | US | mycophenolate mofetil (Cellcept), Cellcept, human interferon beta 1a (Rebif), Rebif | Aaron Boster, EMD Serono, Pfizer | Multiple Sclerosis | 05/12 | 05/12 | | |
| Completed | 1 | 23 | US | ACTH, Acthar Gel, Methylprednisolone, Solumedrol | University of Southern California | Multiple Sclerosis | 06/13 | 07/13 | | |
NCT01766024: Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers |
|
|
| Completed | 1 | 32 | RoW | Interferon beta-1a, BCD-033, Rebif | Biocad | Healthy | 06/13 | 06/13 | | |
NCT02269930: Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers |
|
|
| Completed | 1 | 30 | US | peginterferon beta-1a, BIIB017, Plegridy, Rebif | Biogen | Multiple Sclerosis | 12/14 | 12/14 | | |
NCT02359877: Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers |
|
|
| Completed | 1 | 60 | RoW | BCD-054, pegylated interferon beta 1a, Rebif, interferon beta 1a, Avonex | Biocad | Healthy | 10/15 | 12/15 | | |
RESI, NCT02364986: Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis |
|
|
| Unknown status | 1 | 50 | Europe | Rebif®, Interferon beta 1a, Avonex | PD Dr. Marcus Müller, BfARM, Bonn, DZNE, Bonn | Relapsing-remitting Multiple Sclerosis | 01/17 | 01/17 | | |
